News and Trends 8 May 2020
Phase III Failure Sinks Drug for Rare Neurological Disorder
The Italian biotech Newron is halting the development of the experimental drug sarizotan after it failed to meet efficacy endpoints in phase III, dashing hopes for an approved drug for Rett syndrome. Expectations had been high that the oral drug might be able to treat breathing difficulties associated with the rare genetic disorder after promising […]